 Dose-Response Relationship, Drug
"Dose-Response Relationship, Drug" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The relationship between the dose of an administered drug and the response of the organism to the drug.
| Descriptor ID |
D004305
|
| MeSH Number(s) |
G07.690.220
|
| Concept/Terms |
Dose-Response Relationship, Drug- Dose-Response Relationship, Drug
- Dose-Response Relationships, Drug
- Drug Dose-Response Relationship
- Drug Dose-Response Relationships
- Relationship, Drug Dose-Response
- Relationships, Drug Dose-Response
- Dose Response Relationship, Drug
|
Below are MeSH descriptors whose meaning is more general than "Dose-Response Relationship, Drug".
Below are MeSH descriptors whose meaning is more specific than "Dose-Response Relationship, Drug".
This graph shows the total number of publications written about "Dose-Response Relationship, Drug" by people in this website by year, and whether "Dose-Response Relationship, Drug" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 0 | 6 | 6 | | 1981 | 0 | 5 | 5 | | 1982 | 0 | 8 | 8 | | 1983 | 0 | 6 | 6 | | 1984 | 0 | 4 | 4 | | 1985 | 0 | 8 | 8 | | 1986 | 0 | 7 | 7 | | 1987 | 0 | 12 | 12 | | 1988 | 0 | 10 | 10 | | 1989 | 0 | 18 | 18 | | 1990 | 0 | 24 | 24 | | 1991 | 0 | 25 | 25 | | 1992 | 0 | 28 | 28 | | 1993 | 0 | 39 | 39 | | 1994 | 0 | 29 | 29 | | 1995 | 0 | 29 | 29 | | 1996 | 0 | 22 | 22 | | 1997 | 0 | 32 | 32 | | 1998 | 0 | 32 | 32 | | 1999 | 0 | 35 | 35 | | 2000 | 0 | 47 | 47 | | 2001 | 0 | 55 | 55 | | 2002 | 0 | 72 | 72 | | 2003 | 1 | 71 | 72 | | 2004 | 0 | 75 | 75 | | 2005 | 0 | 68 | 68 | | 2006 | 0 | 65 | 65 | | 2007 | 1 | 63 | 64 | | 2008 | 1 | 66 | 67 | | 2009 | 1 | 54 | 55 | | 2010 | 0 | 58 | 58 | | 2011 | 0 | 57 | 57 | | 2012 | 0 | 55 | 55 | | 2013 | 0 | 42 | 42 | | 2014 | 0 | 51 | 51 | | 2015 | 3 | 42 | 45 | | 2016 | 0 | 40 | 40 | | 2017 | 0 | 29 | 29 | | 2018 | 0 | 40 | 40 | | 2019 | 0 | 29 | 29 | | 2020 | 0 | 5 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Dose-Response Relationship, Drug" by people in Profiles.
-
Huebinger RM, Zaidi HQ, Tataris KL, Weber JM, Pearlman KS, Markul E, Stein-Spencer L, Richards CT. Retrospective Study of Midazolam Protocol for Prehospital Behavioral Emergencies. West J Emerg Med. 2020 Apr 21; 21(3):677-683.
-
Mann D, Antinew J, Knapp L, Almas M, Liu J, Scavone J, Yang R, Modequillo M, Makedonska I, Ortiz M, Kyrychenko A, Nordli D, Farkas V, Farkas MK. Pregabalin adjunctive therapy for focal onset seizures in children 1 month to <4 years of age: A double-blind, placebo-controlled, video-electroencephalographic trial. Epilepsia. 2020 04; 61(4):617-626.
-
Patel NH, Xu J, Saleh T, Wu Y, Lima S, Gewirtz DA. Influence of nonprotective autophagy and the autophagic switch on sensitivity to cisplatin in non-small cell lung cancer cells. Biochem Pharmacol. 2020 05; 175:113896.
-
Nazari F, Oklejas AE, Nör JE, Pearson AT, Jackson TL. In Silico Models Accurately Predict In Vivo Response for IL6 Blockade in Head and Neck Cancer. Cancer Res. 2020 04 01; 80(7):1451-1460.
-
Su Y, Han Y, Liu J, Qiu Y, Tan Q, Zhou Z, Yu YZ, Chen J, Giger ML, Lure FYM, Luo Z. Tailoring steroids in the treatment of COVID-19 pneumonia assisted by CT scans: three case reports. J Xray Sci Technol. 2020; 28(5):885-892.
-
Clark JW, Camidge DR, Kwak EL, Maki RG, Shapiro GI, Chen I, Tan W, Randolph S, Christensen JG, Ozeck M, Tang Y, Wilner KD, Salgia R. Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer. Future Oncol. 2020 Jan; 16(1):4289-4301.
-
Plotkin SR, Duda DG, Muzikansky A, Allen J, Blakeley J, Rosser T, Campian JL, Clapp DW, Fisher MJ, Tonsgard J, Ullrich N, Thomas C, Cutter G, Korf B, Packer R, Karajannis MA. Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. J Clin Oncol. 2019 12 10; 37(35):3446-3454.
-
Turcotte LM, Liu Q, Yasui Y, Henderson TO, Gibson TM, Leisenring W, Arnold MA, Howell RM, Green DM, Armstrong GT, Robison LL, Neglia JP. Chemotherapy and Risk of Subsequent Malignant Neoplasms in the Childhood Cancer Survivor Study Cohort. J Clin Oncol. 2019 12 01; 37(34):3310-3319.
-
O'Donnell PH, Arkenau HT, Sridhar SS, Ong M, Drakaki A, Spira AI, Zhang J, Gordon MS, Degboe AN, Gupta AK, Mukhopadhyay P, Huang W, Abdullah SE, Angra N, Roskos LK, Guo X, Friedlander T. Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108. Cancer. 2020 01 15; 126(2):432-443.
-
Li NS, Liang W, Piccirilli JA, Tang WJ. Reinvestigating the synthesis and efficacy of small benzimidazole derivatives as presequence protease enhancers. Eur J Med Chem. 2019 Dec 15; 184:111746.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|